A Gallup poll released on Monday found that the United States adult obesity rate has dropped to 36.4 percent in 2026, down from a record high of 39.9 percent in 2022. The decline of 3.5 percentage points represents the first statistically meaningful reversal in more than four decades of continuous increase. The rate had risen in nearly every survey since the early 1980s. It rose through recessions, recoveries, wars, pandemics, and across every presidential administration from Reagan to Trump. Then it stopped.
The reason is not ambiguous. Gallup found that 11 percent of American adults now take a GLP-1 receptor agonist for weight loss, up from roughly 3 percent in 2021. That is approximately 29 million people. Awareness of the drug class reached 91 percent, up from 80 percent in 2024. The adoption curve is steeper among women, who account for the larger share of prescriptions, and among adults aged 50 to 64, the cohort where obesity declined most sharply, falling 5 points to 42.8 percent.
GLP-1 receptor agonists work by mimicking a hormone that signals satiety. Semaglutide, sold as Ozempic for diabetes and Wegovy for weight loss, was the first to reach mass-market scale. Tirzepatide, sold as Mounjaro and Zepbound by Eli Lilly, targets both GLP-1 and GIP receptors and has shown greater weight loss in trials. Together, they have created a pharmaceutical category that generated more than $66 billion in global revenue in 2025. Estimates for 2026 range from $80 billion to $100 billion. Morgan Stanley projects the GLP-1 market could reach $190 billion by 2035.
Eli Lilly is now worth $1.13 trillion. Novo Nordisk, which pioneered the category with Ozempic and Wegovy, has collapsed to $225 billion from a peak above $600 billion. The divergence reflects a single product race: Lilly launched orforglipron, an oral GLP-1 for obesity, in the United States during the second quarter of 2026. Novo Nordisk's oral Wegovy tablet reached one million prescriptions within twelve weeks of its launch in January. Both companies are betting that pills will unlock the patients who refused injections.
The clinical results are not in dispute. Patients on semaglutide lose 15 to 17 percent of their body weight. Tirzepatide can produce losses above 20 percent. The effect on comorbidities is profound. Cardiovascular events decline. Type 2 diabetes remits. Sleep apnea improves. The Gallup data now suggest the effect is visible at population scale. The curve that would not bend for four decades is bending.
But a systematic review published in The BMJ in 2026, covering 37 studies and 9,341 adults, found that patients who stopped GLP-1 therapy regained weight at an average rate of 0.8 kilograms per month. For semaglutide and tirzepatide specifically, the projection was return to baseline within approximately 18 months. Patients who lost less than 15 percent of their body weight regained most of what they lost. Only those who lost more than 15 percent retained meaningful reductions after a year off the drug.
The pharmaceutical industry has a word for this. A drug that works only while the patient takes it, that must be taken indefinitely, and that costs more than $1,000 a month at list price, is not a cure. It is a subscription. Wegovy carries a list price of approximately $1,349 per month. Zepbound lists at approximately $1,086. Manufacturer cash-pay programs bring that to $149 to $449, depending on dose and brand. The economics tilt toward lifetime enrollment.
On July 1, the Centers for Medicare and Medicaid Services launched the GLP-1 Bridge, a demonstration program offering eligible Medicare beneficiaries access to Wegovy, Zepbound, and the new oral formulations for $50 per month through December 2027. Beneficiaries qualify at BMI 35 or higher with no additional condition, at BMI 30 or higher with heart failure or uncontrolled hypertension, or at BMI 27 or higher with pre-diabetes or prior cardiovascular events. An estimated 3.8 million beneficiaries meet all program criteria. Participating manufacturers agreed to a reduced net price of approximately $245 per month. The government is absorbing the difference.
The cost to Medicare has not been officially estimated. External analyses describe it as likely to reach billions per year in additional spending. The logic behind it is actuarial. Obesity is the largest single driver of chronic disease costs in the United States. The downstream burden of diabetes, cardiovascular disease, joint replacement, and cancer treatment exceeds what the drugs cost. The Bridge is a bet that subsidizing the subscription saves money over the lifetime of the patient.
The market has already priced this structure. Eli Lilly trades at the valuation of a company whose largest product will be purchased continuously by tens of millions of people for the rest of their lives. The combined GLP-1 revenue of the two leading manufacturers approaches the annual output of entire national health systems. The growth forecasts assume the subscription base expands, not that the underlying condition resolves.
That is the sentence the Gallup data adds. The obesity rate is declining because 29 million Americans take a drug. If they stop, the weight returns. If they keep going, the spending compounds. The government has entered as payer because the alternative costs more. The pharmaceutical companies have entered as utilities because the product is needed indefinitely.
The epidemic that no intervention could reverse for forty years is finally responding. The intervention is a monthly charge. The first population-level decline in American obesity is not a victory over the disease. It is a restructuring of the disease into a recurring cost. The curve bent. The bill is permanent.